Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

52.41 +1.46 (+2.87%)
Official Closing Price Updated: 7:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
90 91 Next >
3 Trends To Watch
Hot topics for 2025 and why. 
Via Talk Markets
Topics Stocks / Equities
Here's How Much $1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth Today
 
Via Benzinga
Don't Buy Weight-Loss Medication From Unauthorized Sources, UK Health Agency Warns About Risks
The MHRA warns against buying weight-loss medicines illegally, emphasizing health risks and the need for prescriptions from licensed professionals to ensure safety. 
Via Benzinga
4 Top Stocks to Buy in January
Here are four stocks to buy now that could offer investors upside in the short and long terms. 
Via The Motley Fool
US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report
Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation. 
Via Benzinga
Should You Buy the Dip in Novo Nordisk Stock Right Now?
Shares of Novo Nordisk are in free fall following lackluster results from a new clinical trial. 
Via The Motley Fool
Novo Nordisk's Options: A Look at What the Big Money is Thinking
 
Via Benzinga
Behind the Scenes of Novo Nordisk's Latest Options Trends
 
Via Benzinga
What Analysts Are Saying About Novo Nordisk Stock
 
Via Benzinga
Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
Stocks soared in 2024, and 2025 could be even stronger. Let's look at key trends, government policies, and sectors poised for growth in the year ahead. 
Via MarketBeat
Topics Economy Energy
While growth is established for NYSE:NVO, the stock's valuation remains reasonable.
For those who appreciate growth without the sticker shock, NYSE:NVO is worth considering. 
Via Chartmill
Will This Major Pharmaceutical Stock Announce a Stock Split in 2025?
Via The Motley Fool
3 Stocks That Could Be Monster Winners in 2025
Via The Motley Fool
Billionaire Philippe Laffont Is Selling Artificial Intelligence Champion Nvidia and Piling Into These Two Industry Leaders
Via The Motley Fool
Topics Artificial Intelligence
10 Top Growth Stocks for 2025
All 10 have had a good 2024, but I believe the best is yet to come. 
Via The Motley Fool
2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades
Via The Motley Fool
Elon Musk Admits To Using Weight Loss Medication Criticized By RFK Jr, Says He Prefers Mounjaro Over Miracle Drug Ozempic
The world's richest man Elon Musk earlier this week admitted to using the weight loss drug Mounjaro. 
Via Benzinga
Prediction: This Will Be Amazon's Next Big Acquisition
Amazon may be known for its retail and tech chops, but the company has also built a strong operation in the healthcare realm over the last several years. 
Via The Motley Fool
Musk Tests Mounjaro, Ozempic, Wegovy: Which Weight-Loss Drug Won Him Over?
Elon Musk sparked conversation about weight-loss drugs and side effects with a Christmas social media post. 
Via Benzinga
Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear.
Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for investors. 
Via The Motley Fool
Down 19% in 1 Day, Is Novo Nordisk Stock Still a Buy?
Via The Motley Fool
Tech Stocks Eye Christmas Gains, Microstrategy Tumbles As Bitcoin Dips To $93,000: What's Driving Markets Monday?
Tech stocks began Christmas week with positive momentum, as the Nasdaq 100 rose 0.4% on Monday, building on a 0.7% gain from Friday. The index has now recovered nearly half of the losses sustained... 
Via Benzinga
Topics Economy
Better Buy: Eli Lilly or Novo Nordisk?
Novo Nordisk stock crashed 17% on Friday after revealing disappointing trial results. 
Via The Motley Fool
Novo Nordisk Rises 5% In Premarket As Analyst Dismisses Friday's 17% Plunge As Market Overreaction
Analysts at Intron Health, led by Naresh Chouhan, suggested that Friday's market reaction was excessively severe. 
Via Benzinga
Novo Nordisk, Super Micro Computer And Arm Are Among Top Large Cap Losers Last Week (December 16-20): Are The Others In Your Portfolio?
11 worst-performing large-cap stocks: NVO, VRTX, XPO, SMCI, NU, ARM, MU, PAYC, CTAS, WBD, MNDY. Blame fiscal spending package, Fed rate hike, weak earnings. 
Via Benzinga
Topics Economy
Is Merck the Next Big Weight-Loss Stock?
Via The Motley Fool
Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug
The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans. 
Via Benzinga
MarketBeat Week in Review – 12/16 - 12/20
Stocks were lower this week after the Federal Reserve confirmed fewer rate cuts in 2025, but Friday's rally suggests hope for a Santa Claus rally remains strong 
Via MarketBeat
Topics Artificial Intelligence Economy
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
Via The Motley Fool
Is Now a Good Time to Buy the Dip in Eli Lilly Stock?
Since Eli Lilly reported third-quarter earnings on Oct. 30, its shares have had a prolonged sell-off. 
Via The Motley Fool
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
90 91 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS